Ewing sarcoma Pipeline to Witness Increased R&D Investment in the Coming Years

  • Published: April 2017

According to a new research report “Ewing sarcoma Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration and Other Developments” published by P&S Intelligence, Ewing sarcoma currently exhibits a strong pipeline with approximately 29 drug candidates.

Explore Report Description at:

Ewing sarcoma Pipeline Analysis

Ewing sarcoma pipeline comprises approximately 29 drug candidates in different stages of development. Ewing sarcoma is a condition in which formation of cancer or tumor takes place in bones and soft tissues. The symptoms associated with Ewing sarcoma include pain as well as swelling in the chest, back, legs, pelvis and arms, lumps in arms, bone fracture, weight loss, loss of appetite, fatigue, malaise, etc.

Pipeline Insights

The pipeline for Ewing sarcoma was analyzed based on the route of administration and it was found that most of the drug candidates are being developed to be administered by oral route.

Major companies collaborate for the development of Ewing sarcoma pipeline

The research also found that various companies are engaged in collaborations for Ewing sarcoma. In April 2014, NanoSmart Pharmaceuticals Inc. and NanoValent Pharmaceuticals Inc., entered into a research collaboration agreement to find out the feasibility of jointly developing an ANA-conjugated liposomal doxorubicin nanoparticle for the treatment of ovarian cancer and other solid tumors.

Novel and patented technologies for Ewing sarcoma pipeline

Novel technologies are being used for Ewing sarcoma drug candidates. MacroGenics Inc., has been using Fc Optimization platform for the development of their drug candidates.
Some of the key players developing Ewing sarcoma therapeutics include Celgene Corporation, Pfizer Inc., and Novartis AG, and others.

Ewing sarcoma Pipeline Analysis

  • By Phase
  • By Route of Administration
  • By Molecule Type
  • By Company